Immunological Assessment and Monitoring in Kidney Transplantation: Being an Outline of an Article for the Nephrology Self-Assessment Program of the American Society of Nephrology
By:
Oriol Bestard Department of Nephrology and Kidney Transplantation, University Hospital Vall d’Hebron, Barcelona, Spain

Nephrology and Kidney Transplantation Laboratory, Vall d’Hebron Research Institute, Barcelona, Spain

Search for other papers by Oriol Bestard in
Current site
Google Scholar
PubMed Close
and
Delphine Kervella Department of Nephrology and Kidney Transplantation, University Hospital Vall d’Hebron, Barcelona, Spain

Nephrology and Kidney Transplantation Laboratory, Vall d’Hebron Research Institute, Barcelona, Spain

Search for other papers by Delphine Kervella in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 5
Published Online:
Dec 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
13
Article Category:
Research Article
Print Publication Date:
01 Dec 2024
Published Online:
Dec 2024
  • 1.

    Hariharan S, Israni AK, Danovitch G: Long-term survival after kidney transplantation. N Engl J Med 385: 729–743, 2021 10.1056/NEJMra2014530 PubMed

  • 2.

    Hariharan S, Rogers N, Naesens M, Pestana JM, Ferreira GF, Requião-Moura LR, et al.: Long-term kidney transplant survival across the globe. Transplantation 108: e254–e263, 2024 10.1097/TP.0000000000004977 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al.: The Banff 2019 Kidney Meeting report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. Am J Transplant 20: 2318–2331, 2020 10.1111/ajt.15898 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Naesens M, Anglicheau D: Precision transplant medicine: Biomarkers to the Rescur. J Am Soc Nephrol 29: 24–34, 2018 10.1681/ASN.2017010004 PubMed

  • 5.

    Park S, Sellares J, Tinel C, Anglicheau D, Bestard O, Friedewald JJ: European Society of Organ Transplantation consensus statement on Testingtfor non-invasive diagnosis of kidney allograft rejection. Transpl Int 36: 12115, 2023 10.3389/ti.2023.12115 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Tambur AR, Bestard O, Campbell P, Chong AS, Barrio MC, Ford ML, et al.: Sensitization in transplantation: Assessment of Risk 2022 Working Group Meeting report. Am J Transplant 23: 133–149, 2023 10.1016/j.ajt.2022.11.009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lefaucheur C, Louis K, Morris AB, Taupin J-L, Nickerson P, Tambur AR, STAR 2022 Working Group, et al.: Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A sensitization in transplantation: Assessment of risk consensus document. Am J Transplant 23: 115–132, 2023 10.1016/j.ajt.2022.11.013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Senev A, Coemans M, Lerut E, Van Sandt V, Kerkhofs J, Daniëls L, et al.: Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: An observational cohort study. J Am Soc Nephrol 31: 2193–2204, 2020 10.1681/ASN.2020010019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, Nickerson PW: The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant 15: 2197–2202, 2015 10.1111/ajt.13341 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Meneghini M, Crespo E, Niemann M, Torija A, Lloberas N, Pernin V, et al.: Donor/recipient HLA molecular mismatch scores predict primary humoral and cellular alloimmunity in kidney transplantation. Front Immunol 11: 623276, 2020 10.3389/fimmu.2020.623276 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Hricik DE, Augustine J, Nickerson P, Formica RN, Poggio ED, Rush D, CTOT-01 consortium, et al.: Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: Results from the CTOT-01 multicenter study. Am J Transplant 15: 3166–3173, 2015 10.1111/ajt.13401 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Bestard O, Meneghini M, Crespo E, Bemelman F, Koch M, Volk HD, et al.: Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. Am J Transplant 21: 2833–2845, 2021 10.1111/ajt.16563 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Snanoudj R, Kamar N, Cassuto E, Caillard S, Metzger M, Merville P, et al.: Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney Int 95: 1471–1485, 2019 10.1016/j.kint.2018.12.029 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Maguire C, Crivello P, Fleischhauer K, Isaacson D, Casillas A, Kramer CSM, et al.: Qualitative, rather than quantitative, differences between HLA-DQ alleles affect HLA-DQ immunogenicity in organ transplantation. HLA 103: e15455, 2024 10.1111/tan.15455 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, et al.: Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant 19: 3100–3113, 2019 10.1111/ajt.15414 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Meneghini M, Perona A, Crespo E, Bemelman F, Reinke P, Viklicky O, et al.: On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes. Front Immunol 13: 924825, 2022 10.3389/fimmu.2022.924825 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al.: IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 377: 442–453, 2017 10.1056/NEJMoa1612567 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Vincenti F, Bestard O, Brar A, Cruzado JM, Seron D, Gaber AO, et al.: Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant. J Am Soc Nephrol 35: 347–360, 2024 10.1681/ASN.0000000000000287 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Pilon C, Joher N, Usureau C, Boutin E, Boueilh A, Taupin J-L, et al.: Open-label phase 1/2 study of daratumumab-based desensitization before kidney transplantation. Kidney Int Rep 9: 3250–3264, 2024 10.1016/j.ekir.2024.08.020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, et al.: Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol 28: 3353–3362, 2017 10.1681/ASN.2017030287 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Hricik DE, Formica RN, Nickerson P, Rush D, Fairchild RL, Poggio ED, Clinical Trials in Organ Transplantation-09 Consortium, et al.: Adverse outcomes of tacrolimus withdrawal in immune–quiescent kidney transplant recipients. J Am Soc Nephrol 26: 3114–3122, 2015 10.1681/ASN.2014121234 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Bertrand D, Gatault P, Jauréguy M, Garrouste C, Sayegh J, Bouvier N, et al.: Protocol biopsies in patients with subclinical de novo donor-specific antibodies after kidney transplantation: A multicentric study. Transplantation 104: 1726–1737, 2020 10.1097/TP.0000000000003055 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Stringer D, Gardner L, Shaw O, Clarke B, Briggs D, Worthington J, et al.: Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): A randomised controlled trial. eClinicalMedicine 56: 101819, 2023 10.1016/j.eclinm.2022.101819 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Bertrand D, Gatault P, Jauréguy M, Garrouste C, Duveau A, Bouvier N, et al.: Protocol biopsies in patients with subclinical de novo DSA after kidney transplantation: Long-term graft survival. Transplantation 108: e204–e206, 2024 10.1097/TP.0000000000005061 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al.: Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 expert consensus from the Transplantation Society Working Group. Transplantation 104: 911–922, 2020 10.1097/TP.0000000000003095 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, et al.: A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med 391: 122–132, 2024 10.1056/NEJMoa2400763 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen J-P, Vernerey D, Aubert O, et al.: IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 27: 293–304, 2016 10.1681/ASN.2014111120 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, et al.: Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 28: 702–715, 2017 10.1681/ASN.2016030368 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, et al.: Prediction system for risk of allograft loss in patients receiving kidney transplants: International derivation and validation study. BMJ 366: l4923, 2019 10.1136/bmj.l4923 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, et al.: De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant 18: 1783–1789, 2018 10.1111/ajt.14721 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Kitchens WH, Larsen CP, Badell IR: Costimulatory blockade and solid organ transplantation: The past, present, and future. Kidney Int Rep 8: 2529–2545, 2023 10.1016/j.ekir.2023.08.037 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT: The emerging field of non–human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100: 787–798, 2021 10.1016/j.kint.2021.04.044 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Goutaudier V, Danger R, Catar RA, Racapé M, Philippe A, Elias M, EU-TRAIN Consortium, et al.: Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN). Kidney Int 106: 943–960, 2024 10.1016/j.kint.2024.07.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    See SB, Mantell BS, Clerkin KJ, Ray B, Vasilescu ER, Marboe CC, et al.: Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. Am J Transplant 20: 2571–2580, 2020 10.1111/ajt.15871 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Bestard O, Nickel P, Cruzado JM, Schoenemann C, Boenisch O, Sefrin A, et al.: Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 19: 1419–1429, 2008 10.1681/ASN.2007050539 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Bestard O, Crespo E, Stein M, Lúcia M, Roelen DL, de Vaal YJ, et al.: Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 13: 1880–1890, 2013 10.1111/ajt.12285 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Ashoor I, Najafian N, Korin Y, Reed EF, Mohanakumar T, Ikle D, et al.: Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 13: 1871–1879, 2013 10.1111/ajt.12286 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Augustine JJ, Siu DS, Clemente MJ, Schulak JA, Heeger PS, Hricik DE: Pre-transplant IFN-γ ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 5: 1971–1975, 2005 10.1111/j.1600-6143.2005.00958.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Andree H, Nickel P, Nasiadko C, Hammer MH, Schönemann C, Pruss A, et al.: Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 17: 573–580, 2006 10.1681/ASN.2005030299 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Gandolfini I, Crespo E, Baweja M, Jarque M, Donadei C, Luque S, et al.: Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation. Plos ONE 13: e0200696, 2018 10.1371/journal.pone.0200696 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Montero N, Farouk S, Gandolfini I, Crespo E, Jarque M, Meneghini M, et al.: Pretransplant donor-specific IFNγ ELISPOT as a predictor of graft rejection: A diagnostic test accuracy meta-analysis. Transplant Direct 5: e451, 2019 10.1097/TXD.0000000000000886 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Bestard O, Cruzado JM, Lucia M, Crespo E, Casis L, Sawitzki B, et al.: Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 84: 1226–1236, 2013 10.1038/ki.2013.236 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Crespo E, Vidal-Alabró A, Jouve T, Fontova P, Stein M, Mocka S, et al.: Tacrolimus CYP3A single-nucleotide polymorphisms and preformed T- and B-cell alloimmune memory improve current pretransplant rejection-risk stratification in kidney transplantation. Front Immunol 13: 869554, 2022 10.3389/fimmu.2022.869554 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Crespo E, Cravedi P, Martorell J, Luque S, Melilli E, Cruzado JM, et al.: Posttransplant peripheral blood donor–specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Kidney Int 92: 201–213, 2017 10.1016/j.kint.2016.12.024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    DeWolf S, Grinshpun B, Savage T, Lau SP, Obradovic A, Shonts B, et al.: Quantifying size and diversity of the human T cell alloresponse. JCI Insight 3; e121256, 2018 10.1172/jci.insight.121256 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Aschauer C, Jelencsics K, Hu K, Heinzel A, Gregorich MG, Vetter J, et al.: Prospective tracking of Ddonor-reactive T-cell clones in the circulation and rejecting human kidney allografts. Front Immunol 12: 750005, 2021 10.3389/fimmu.2021.750005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Aschauer C, Jelencsics K, Hu K, Gregorich M, Reindl-Schwaighofer R, Wenda S, et al.: Effects of reduced-dose anti-human T-lymphocyte globulin on overall and donor-specific T-cell repertoire reconstitution in sensitized kidney transplant recipients. Front Immunol 13: 843452, 2022 10.3389/fimmu.2022.843452 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Morris H, DeWolf S, Robins H, Sprangers B, LoCascio SA, Shonts BA, et al.: Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med 7: 272ra10, 2015 10.1126/scitranslmed.3010760 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Jacquemont L, Tilly G, Yap M, Doan-Ngoc T-M, Danger R, Guérif P, et al.: Terminally differentiated effector memory CD8+ T cells identify kidney transplant recipients at high risk of graft failure. J Am Soc Nephrol 31: 876–891, 2020 10.1681/ASN.2019080847 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Mai HL, Degauque N, Le Bot S, Rimbert M, Renaudin K, Danger R, et al.: Antibody-mediated allograft rejection is associated with an increase in peripheral differentiated CD28−CD8+ T cells – Analyses of a cohort of 1032 kidney transplant recipients. eBioMedicine 83: 104226, 2022 10.1016/j.ebiom.2022.104226 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Mathews DV, Wakwe WC, Kim SC, Lowe MC, Breeden C, Roberts ME, et al.: Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells. Am J Transplant 17: 2285–2299, 2017 10.1111/ajt.14349 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Cortes-Cerisuelo M, Laurie SJ, Mathews DV, Winterberg PD, Larsen CP, Adams AB, et al.: Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients. Am J Transplant 17: 2350–2362, 2017 10.1111/ajt.14350 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Espinosa J, Herr F, Tharp G, Bosinger S, Song M, Farris AB, et al.: CD57+ CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant 16: 1102–1112, 2016 10.1111/ajt.13613 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Cano-Romero FL, Laguna Goya R, Utrero-Rico A, Gómez-Massa E, Arroyo-Sánchez D, Suárez-Fernández P, et al.: Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients. Am J Transplant 19: 89–97, 2019 10.1111/ajt.14987 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Désy O, Béland S, Thivierge M-P, Marcoux M, Desgagnés J-S, Bouchard-Boivin F, et al.: T follicular helper cells expansion in transplant recipients correlates with graft infiltration and adverse outcomes. Front Immunol 15: 1275933, 2024 10.3389/fimmu.2024.1275933 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Louis K, Macedo C, Bailly E, Lau L, Ramaswami B, Marrari M, et al.: Coordinated circulating T follicular helper and activated B cell responses underlie the onset of antibody-mediated rejection in kidney transplantation. J Am Soc Nephrol 31: 2457–2474, 2020 10.1681/ASN.2020030320 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Kervella D, Torija A, Zúñiga JM, Bestard O: How to measure human leukocyte antigen-specific B cells. Curr Opin Organ Transplant 28: 345–354, 2023 10.1097/MOT.0000000000001097 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Luque S, Lúcia M, Crespo E, Jarque M, Grinyó JM, Bestard O: A multicolour HLA-specific B-cell FluoroSpot assay to functionally track circulating HLA-specific memory B cells. J Immunol Methods 462: 23–33, 2018 10.1016/j.jim.2018.07.011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Snanoudj R, Claas FHJ, Heidt S, Legendre C, Chatenoud L, Candon S: Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int 87: 1230–1240, 2015 10.1038/ki.2014.390 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Wehmeier C, Karahan GE, Krop J, de Vaal Y, Langerak-Langerak J, Binet I, Swiss Transplant Cohort Study, et al.: Donor-specific B cell memory in alloimmunized kidney transplant recipients: First clinical application of a novel method. Transplantation 104: 1026–1032, 2020 10.1097/TP.0000000000002909 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Altulea D, van den Born JC, Diepstra A, Bungener L, Terpstra D, Hepkema BG, et al.: Memory B-cell derived donor-specific antibodies do not predict outcome in sensitized kidney transplant recipients: A retrospective single-center study. Front Immunol 15: 1360627, 2024 10.3389/fimmu.2024.1360627 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Lúcia M, Luque S, Crespo E, Melilli E, Cruzado JM, Martorell J, et al.: Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney Int 88: 874–887, 2015 10.1038/ki.2015.205 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Luque S, Lúcia M, Melilli E, Lefaucheur C, Crespo M, Loupy A, et al.: Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation. Am J Transplant 19: 368–380, 2019 10.1111/ajt.15055 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Bestard O, Grinyó J: Refinement of humoral rejection effector mechanisms to identify specific pathogenic histological lesions with different graft outcomes. Am J Transplant 19: 952–953, 2019 10.1111/ajt.15171 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Torija A, Matignon M, Vincenti F, Casanova-Ferrer F, Pilon C, Tambur AR, et al.: Anti-HLA serological response to CD38-targeting desensitization therapy is challenged by peripheral memory B-cells in highly sensitized kidney transplant candidates [published online ahead of print Aug 10, 2024]. Am J Transplant doi:10.1016/j.ajt.2024.08.004 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Song S, Manook M, Kwun J, Jackson AM, Knechtle SJ, Kelsoe G: Allo-specific humoral responses: New methods for screening donor-specific antibody and characterization of HLA-specific memory B cells. Front Immunol 12: 705140, 2021 10.3389/fimmu.2021.705140 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Kramer CSM, Franke-van Dijk MEI, Bakker KH, Uyar-Mercankaya M, Karahan GE, Roelen DL, et al.: Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR. Am J Transplant 20: 3341–3353, 2020 10.1111/ajt.15950 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Burton H, McLaughlin L, Shiu KY, Shaw O, Mamode N, Spencer J, et al.: The phenotype of HLA-binding B cells from sensitized kidney transplant recipients correlates with clinically prognostic patterns of interferon-γ production against purified HLA proteins. Kidney Int International 102: 355–369, 2022 10.1016/j.kint.2022.02.041 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Smith MJ, Packard TA, O’Neill SK, Hinman RM, Rihanek M, Gottlieb PA, et al.: Detection and enrichment of rare antigen-specific B cells for analysis of phenotype and function. J Vis Exp : 55382, 2017 10.3791/55382 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Cherukuri A, Abou-Daya KI, Chowdhury R, Mehta RB, Hariharan S, Randhawa P, et al.: Transitional B cell cytokines risk stratify early borderline rejection after renal transplantation. Kidney Int 103: 749–761, 2023 10.1016/j.kint.2022.10.026 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Elias C, Chen C, Cherukuri A: Regulatory B cells in solid organ transplantation: From immune monitoring to immunotherapy. Transplantation 108: 1080–1089, 2024 10.1097/TP.0000000000004798 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, et al.: A peripheral blood gene expression signature to diagnose subclinical acute rejection. J Am Soc Nephrol 30: 1481–1494, 2019 10.1681/ASN.2018111098 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Akalin E, Weir MR, Bunnapradist S, Brennan DC, Delos Santos R, Langone A, et al.: Clinical validation of an immune quiescence gene expression signature in kidney transplantation. Kidney360 2: 1998–2009, 2021 10.34067/KID.0005062021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Friedewald JJ, Kurian SM, Heilman RL, Whisenant TC, Poggio ED, Marsh C, Clinical Trials in Organ Transplantation 08 (CTOT-08), et al.: Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant 19: 98–109, 2019 10.1111/ajt.15011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Van Loon E, Gazut S, Yazdani S, Lerut E, de Loor H, Coemans M, et al.: Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. EBioMedicine 46: 463–472, 2019 10.1016/j.ebiom.2019.07.028 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Danger R, Le Berre L, Cadoux M, Kerleau C, Papuchon E, Mai HL, DIVAT Consortium, et al.: Subclinical rejection-free diagnostic after kidney transplantation using blood gene expression. Kidney Int 103: 1167–1179, 2023 10.1016/j.kint.2023.03.019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Van Loon E, Giral M, Anglicheau D, Lerut E, Dubois V, Rabeyrin M, et al.: Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study. Am J Transplant 21: 740–750, 2021 10.1111/ajt.16179 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Sellarés J, Casanova F, Perez-Saez MJ, Cucchiari D, Coloma A, Vila A, et al.: Blood gene expression profiling and donor-derived cell-free DNA to noninvasively diagnose clinical and subclinical kidney transplant rejection: A real-life appraisal study. Transplantation 10.1097/TP.0000000000005257

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Bestard O, Augustine J, Wee A, Poggio E, Mannon RB, Ansari MJ, et al.: Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection. Am J Transplant 24: 436–447, 2024 10.1016/j.ajt.2023.09.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, et al.: The kSORT assay to detect renal transplant patients at high risk for acute rejection: Results of the multicenter AART study. PLOS Med 11: e1001759, 2014 10.1371/journal.pmed.1001759 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Zhang W, Yi Z, Wei C, Keung KL, Sun Z, Xi C, et al.: Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight 4: e127543, 2019 10.1172/jci.insight.127543 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Van Loon E, Lerut E, de Loor H, Kuypers D, Emonds M-P, Anglicheau D, et al.: Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: Performance of the peripheral blood 8-gene expression assay. Nephrol Dial Transplant 35: 1328–1337, 2020 10.1093/ndt/gfaa096 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Pineda S, Sur S, Sigdel T, Nguyen M, Crespo E, Torija A, et al.: Peripheral blood RNA sequencing unravels a differential signature of coding and noncoding genes by types of kidney allograft rejection. Kidney Int Rep 5: 1706–1721, 2020 10.1016/j.ekir.2020.07.023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Park S, Guo K, Heilman RL, Poggio ED, Taber DJ, Marsh CL, et al.: Combining blood gene expression and cellfree DNA to diagnose subclinical rejection in kidney transplant recipients. Clin J Am Soc Nephrol 16: 1539–1551, 2021 10.2215/CJN.05530421 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Aubert O, Ursule-Dufait C, Brousse R, Gueguen J, Racapé M, Raynaud M, et al.: Cell-free DNA for the detection of kidney allograft rejection. Nat Med 30: 2320–2327, 2024 10.1038/s41591-024-03087-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Bu L, Gupta G, Pai A, Anand S, Stites E, Moinuddin I, et al.: Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int 101: 793–803, 2022 10.1016/j.kint.2021.11.034 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Gauthier PT, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, Halloran PF, Trifecta-Kidney Investigators, et al.: Distinct molecular processes mediate donor-derived cell-free DNA release from kidney transplants in different disease states. Transplantation 108: 898–910, 2024 10.1097/TP.0000000000004877 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators, et al.: Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol 28: 2221–2232, 2017 10.1681/ASN.2016091034 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Billings P, Trifecta Investigators, et al.: The Trifecta study: Comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol 33: 387–400, 2022 10.1681/ASN.2021091191 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, the Trifecta Investigators, et al.: Antibody-mediated rejection without detectable donor-specific antibody releases donor-derived cell-free DNA: Results from the Trifecta study. Transplantation 107: 709–719, 2023 10.1097/TP.0000000000004324 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, et al.: Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 11: 2228–2234, 2011 10.1111/j.1600-6143.2011.03680.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Tinel C, Devresse A, Vermorel A, Sauvaget V, Marx D, Avettand-Fenoel V, et al.: Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. Am J Transplant 20: 3462–3476, 2020 10.1111/ajt.15959 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Van Loon E, Tinel C, de Loor H, Bossuyt X, Callemeyn J, Coemans M, et al.: Automated urinary chemokine assays for noninvasive detection of kidney transplant rejection: A prospective cohort study. Am J Kidney Dis 83: 467–476, 2024 10.1053/j.ajkd.2023.07.022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Hirt-Minkowski P, Handschin J, Stampf S, Hopfer H, Menter T, Senn L, et al.: Randomized trial to assess the clinical utility of renal allograft monitoring by urine CXCL10 chemokine. J Am Soc Nephrol 34: 1456–1469, 2023 10.1681/ASN.0000000000000160 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Suthanthiran M, Schwartz JE, Ding R, et al.: Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 369: 20–31, 2013 10.1056/NEJMoa1215555 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    El Fekih R, Hurley J, Tadigotla V, Alghamdi A, Srivastava A, Coticchia C, et al.: Discovery and validation of a urinary exosome mRNA signature for the diagnosis of human kidney transplant rejection. J Am Soc Nephrol 32: 994–1004, 2021 10.1681/ASN.2020060850 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Yang JYC, Sarwal RD, Sigdel TK, Damm I, Rosenbaum B, Liberto JM, et al.: A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection. Sci Transl Med 12: eaba2501, 2020 10.1126/scitranslmed.aba2501 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Bestard O, Couzi L, Crespo M, Kessaris N, Thaunat O: Stratifying the humoral risk of candidates to a solid organ transplantation: A proposal of the ENGAGE working group. Transpl Int 34: 1005–1018, 2021 10.1111/tri.13874 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Chemouny J-M, Suberbielle C, Rabant M, Zuber J, Alyanakian M-A, Lebreton X, et al.: De novo donor-specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection. Transplantation 99: 965–972, 2015 10.1097/TP.0000000000000448 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Johnson AC, Zhang J, Karadkhele G, Gragert L, Hertzberg V, Larsen CP: Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation. Am J Transplant 24: 260–270, 2024 10.1016/j.ajt.2023.09.011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Tinckam KJ, Rose C, Hariharan S, Gill J: Re-examining risk of repeated HLA mismatch in kidney transplantation. J Am Soc Nephrol 27: 2833–2841, 2016 10.1681/ASN.2015060626 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 213 213 146
Full Text Views 270 270 239
PDF Downloads 403 403 360